SIBO vs IBS vs IBD: How To Tell Them Apart in 2026

If you are reading this, you have probably been told one of three things by a doctor: that you have irritable bowel syndrome (IBS), that you might have small intestinal bacterial overgrowth (SIBO), or that inflammatory bowel disease (IBD) needs to be ruled out. The three conditions share enough symptoms to be confused for one another. They are not the same. The diagnostic path matters, the test panels are different, and the treatments are not interchangeable.

This page is the plain-English version of the differential diagnosis a gastroenterologist works through. It covers what each condition actually is, how it is diagnosed, the red flags that change everything, where the conditions overlap, and where gut-directed hypnotherapy (GDH) fits. The short answer for treatment fit: GDH is first-line evidence-based therapy for IBS, an adjunct in SIBO management, and supportive only for IBS-pattern overlay symptoms in IBD that is otherwise in remission.

Strip away the jargon and the three conditions divide along a clean axis: what is broken, and where.

• IBS (Irritable Bowel Syndrome) is a functional gut-brain disorder. The plumbing is structurally normal. Bowel imaging, endoscopy, and inflammatory markers all come back clean. What is dysregulated is how the nervous system, motility, and microbial environment interact. Diagnosis is clinical, anchored to the Rome IV criteria, and made after red flags are excluded.
• SIBO (Small Intestinal Bacterial Overgrowth) is a microbial problem. Bacteria that normally live in the colon migrate into or proliferate in the small intestine, where they are not supposed to be in those numbers. Diagnosis is by breath testing (hydrogen, methane, increasingly hydrogen sulfide). The driver is usually a motility issue, structural anomaly, or impaired gastric/pancreatic function.
• IBD (Inflammatory Bowel Disease) is an immune-mediated chronic inflammation of the bowel. Crohn's disease can affect anywhere from mouth to anus and goes through the bowel wall; ulcerative colitis is limited to the colon and stays superficial. Diagnosis requires endoscopy with biopsy and is supported by inflammatory markers (fecal calprotectin, C-reactive protein) and imaging.

Overlap is real and clinically common. Roughly 30 to 50 percent of people with diarrhea-predominant IBS may have an underlying SIBO picture on breath testing. People with IBD in objective remission can still carry IBS-pattern symptoms (post-inflammatory IBS-like syndrome). And SIBO can be triggered by the slowed motility that goes with both IBS and IBD. The three diagnoses are not mutually exclusive.

With that orientation in hand, here is each condition in more detail.

Irritable bowel syndrome is a functional gastrointestinal disorder. That phrase has a specific meaning. It does not mean the symptoms are imaginary or psychological in any dismissive sense. It means that when a clinician investigates the bowel structurally (endoscopy, imaging, blood inflammatory markers, stool inflammatory markers), nothing visibly abnormal is found, yet the symptoms are real, reproducible, and meet a defined clinical pattern. The dysregulation lives in the way the gut and the central nervous system communicate, in motility, in visceral sensation, and in the bidirectional signalling sometimes described as the gut-brain axis. For a deeper walk through what actually drives the symptoms, see our guide to underlying mechanisms in IBS.

The Rome IV definition

IBS is a positive clinical diagnosis, not a diagnosis of exclusion. The current standard is the Rome IV criteria: recurrent abdominal pain on average at least one day per week in the last three months, associated with two or more of (a) defecation, (b) a change in stool frequency, or (c) a change in stool form. Symptoms must have started at least six months before diagnosis. That is the baseline pattern. Once Rome IV is satisfied and red flags are absent, IBS can be diagnosed without exhaustive testing.

The four IBS subtypes

IBS is then sub-classified by stool pattern, because the subtype meaningfully changes treatment selection.

• IBS-D (diarrhea-predominant): more than 25 percent of stools are loose or watery, less than 25 percent are hard.
• IBS-C (constipation-predominant): more than 25 percent of stools are hard or lumpy, less than 25 percent are loose.
• IBS-M (mixed): more than 25 percent of stools are loose and more than 25 percent are hard.
• IBS-U (unclassified): meets IBS criteria but the stool pattern does not clearly fit the other three.

Subtype is not fixed. It can shift over time, with stress, with diet changes, or with the natural history of the condition. A patient can move between subtypes in the same year. This matters clinically because antispasmodics, motility agents, low-FODMAP, and gut-brain therapies are weighted differently for each subtype.

The mechanisms

The current best-evidence picture of what drives IBS pulls together several overlapping factors:

• Visceral hypersensitivity. The bowel becomes more sensitive to normal stretch and pressure. Sensations that healthy individuals do not perceive at all (gas movement, normal peristalsis, the postprandial gastrocolic response) are interpreted by the IBS-pattern nervous system as pain or urgency.
• Gut-brain axis dysregulation. Bidirectional signalling between the enteric nervous system and the central nervous system runs hot. Stress amplifies symptoms; symptoms amplify stress; the loop self-reinforces.
• Motility abnormalities. Some IBS patients have measurably faster or slower transit, exaggerated post-meal contractions, or disordered colonic motor patterns.
• Microbiome shifts. Many IBS patients show reduced microbial diversity and altered ratios compared to controls. Whether this is cause, consequence, or marker is still being worked out.
• Post-infectious onset. A meaningful subset of IBS begins after an episode of gastroenteritis. Post-infectious IBS is its own well-described subgroup with distinct mechanisms involving low-grade immune activation and altered gut barrier function.

For most patients, several of these factors are running at once, in different proportions. That is why no single intervention works for everyone, and why combining a structural intervention (diet) with a gut-brain intervention (hypnotherapy, CBT-for-IBS) often outperforms either in isolation.

How common is IBS, and who gets it

IBS is one of the most common conditions seen in primary care and gastroenterology. Population prevalence estimates run between 5 and 15 percent depending on the country, the criteria used, and the diagnostic threshold. Women are diagnosed roughly two to three times as often as men, although the reasons for that gap (true biological difference, healthcare-seeking behaviour, diagnostic patterns) are still debated. Onset is most often in the late teens, twenties, or thirties, though new presentations can happen at any age.

The condition runs a chronic, relapsing-remitting course in most patients. Symptom severity typically waxes and wanes, with periods of relative quiet interrupted by flares triggered by stress, dietary changes, illness, hormonal shifts, or sometimes nothing identifiable at all. The natural history is usually not a steady deterioration; it is a fluctuating pattern that can be substantially modified with the right combination of interventions.

What IBS is not

A few things worth ruling out explicitly because they often get conflated with IBS in popular discussion. IBS is not a precursor to IBD. The two conditions do not progress into one another. Having IBS does not raise your risk of developing Crohn's disease or ulcerative colitis later. IBS is not a precursor to colorectal cancer either. The lifetime cancer risk in IBS patients is the same as the general population. IBS is not a food allergy or food intolerance, although food triggers are common and dietary management is an important treatment lever. And IBS is not, in any meaningful clinical sense, a psychiatric condition. The gut-brain dysregulation that drives it is real and physiological, even though psychological interventions can powerfully help, exactly because the brain has a real bidirectional connection to gut function.

SIBO is a microbial pathology. The healthy small intestine has relatively few bacteria compared to the colon. Gastric acid, pancreatic and biliary secretions, the migrating motor complex (the housekeeping wave that sweeps the small intestine between meals), and the ileocecal valve all work together to keep colonic-style bacterial densities out of the small bowel. When one or more of those defenses fails, bacteria proliferate where they should not, ferment carbohydrates locally, produce gas immediately after meals, and disrupt absorption.

How SIBO is diagnosed

The diagnostic gold standard is technically jejunal aspirate culture, but in routine clinical practice the breath test is the workhorse. After an overnight fast and a low-fermentable preparatory diet the day before, you drink a measured dose of either glucose or lactulose. The lab samples your breath at baseline and at regular intervals for the next 90 to 180 minutes, measuring exhaled hydrogen and methane (and increasingly hydrogen sulfide).

The interpretation rests on timing and gas type. A defined early rise in hydrogen suggests that bacteria in the small intestine, not the colon, are fermenting the substrate. An elevated baseline methane or sustained methane rise suggests intestinal methanogen overgrowth (IMO), which is now treated as a related but distinct entity from classic hydrogen-dominant SIBO.

Breath testing is imperfect. False positives and false negatives both occur, methodology varies between labs, and the field has moved several times in the last decade on what counts as a positive result. North American consensus statements have tightened the criteria, and most clinicians now interpret breath tests in the context of the clinical picture rather than treating the number as a verdict.

SIBO subtypes

• Hydrogen-dominant SIBO. Classic presentation. Predominantly bloating, distension, and diarrhea. The bacterial population skews toward hydrogen-producing species.
• Methane-dominant (intestinal methanogen overgrowth, IMO). Driven by archaea (methanogens), not bacteria in the strict sense. More associated with constipation, hard stool, and slower transit. Often requires a different antimicrobial combination.
• Hydrogen sulfide SIBO. Increasingly recognised as a distinct entity. Associated with sulfur-rich food intolerance, diarrhea, and a particular pattern of breath gas. Newer breath test panels measure it directly.

How SIBO is treated

Treatment usually combines an antimicrobial phase, a motility/prokinetic phase, and a dietary phase, with the exact composition adjusted to the subtype.

• Targeted antibiotics. Rifaximin is the most studied agent for hydrogen-dominant SIBO. For IMO, a combination of rifaximin and neomycin (or metronidazole) is more often used. Herbal antimicrobial protocols are an alternative with some supporting evidence.
• Prokinetics. Because motility failure is the most common underlying driver, many protocols add a low-dose prokinetic between meals to support the migrating motor complex and reduce recurrence.
• Dietary intervention. Low-fermentable approaches (low-FODMAP, SIBO-specific diets, or elemental diets in severe cases) reduce substrate for fermentation and ease symptoms while the antimicrobial work happens.
• Address the driver. The hardest and most overlooked piece. SIBO recurs in a high percentage of patients within a year if the underlying motility issue, structural anomaly (adhesions, diverticula, ileocecal valve dysfunction), or upstream condition (proton pump inhibitor use, hypochlorhydria, scleroderma, prior bowel surgery) is not also addressed.

Where GDH fits in this picture is supportive, not curative. SIBO is a microbial problem; hypnotherapy does not eradicate bacteria. What it can do is reduce the visceral hypersensitivity, anxiety, and post-meal gut-brain reactivity that often persist even after a successful antimicrobial course. For patients running combined SIBO and IBS pictures, GDH is most often run alongside or after the antimicrobial phase rather than as a substitute. See how we position GDH as adjunct to SIBO treatment for the full clinical framing.

Common SIBO drivers and risk factors

One of the most useful pieces of clinical reasoning in SIBO is to ask not just whether bacterial overgrowth is present, but why. The recurrence rate of SIBO within 9 to 12 months of antimicrobial treatment is high in published series, and the leading explanation is that the underlying driver was never addressed. The list of common contributors includes:

• Impaired migrating motor complex (MMC). The fasting-state housekeeping wave that sweeps the small intestine between meals. When the MMC weakens, bacteria are not regularly cleared, and overgrowth develops.
• Prior gastrointestinal infection. Post-infectious IBS commonly co-occurs with SIBO, and the same antibodies (anti-CdtB and anti-vinculin) that drive post-infectious motility changes are implicated in both.
• Structural anomalies. Strictures, adhesions from prior abdominal surgery, surgical bypass, diverticula, ileocecal valve dysfunction, or any anatomical change that creates a stagnant pocket.
• Hypochlorhydria. Reduced gastric acid (from long-term proton pump inhibitor use, prior gastric surgery, autoimmune gastritis, or simple aging) lowers the natural barrier to bacterial entry into the upper gut.
• Pancreatic insufficiency. Reduced digestive enzymes leave more substrate available for bacterial fermentation upstream.
• Connective tissue disorders. Scleroderma, Ehlers-Danlos syndrome, and similar conditions can affect bowel motility and predispose to overgrowth.
• Diabetes with autonomic neuropathy. Slows gastric emptying and small bowel transit.
• Repeated antibiotic exposure. Disrupts normal microbial balance and can paradoxically set the stage for overgrowth of antibiotic-resistant species.

Identifying which driver is at work in a given patient is what separates a one-time antimicrobial course (often followed by recurrence) from a durable treatment plan. This is gastroenterology and integrative medicine work, not hypnotherapy work, but it informs why GDH is positioned where it is positioned in the overall sequence.

Inflammatory bowel disease is a chronic, immune-mediated inflammation of the gastrointestinal tract. The two main forms behave differently and require different management.

Crohn's disease

Crohn's can affect any part of the gastrointestinal tract from mouth to anus, though the terminal ileum and colon are the most common locations. The inflammation is transmural (it goes through the full thickness of the bowel wall) and skip-pattern (segments of inflamed bowel are interspersed with healthy segments). This pattern explains many of the characteristic complications: fistulas, strictures, abscesses, and the increased risk of needing surgical resection.

Ulcerative colitis

Ulcerative colitis is limited to the colon and the rectum, the inflammation is continuous (no skip lesions), and it stays in the superficial mucosal layer rather than going through the bowel wall. Bloody diarrhea is the most characteristic symptom because the surface mucosa is what bleeds. Severity ranges from proctitis (just the rectum) to pancolitis (the entire colon).

How IBD is diagnosed

IBD diagnosis is anchored in three layers of evidence: clinical history, biochemical markers, and direct visualisation with biopsy. The standard workup includes:

• Bloodwork. Complete blood count (looking for anemia and elevated white cells), C-reactive protein (CRP, a systemic inflammation marker), ferritin and iron studies, electrolytes, liver enzymes, and albumin (which can drop in active disease).
• Stool fecal calprotectin. A bowel-specific inflammatory marker. Calprotectin is one of the most useful single tests for separating IBD from IBS in primary care. Low calprotectin in someone with IBS-pattern symptoms is reassuring; elevated calprotectin pushes the workup toward endoscopy.
• Endoscopy with biopsy. The diagnostic standard. Colonoscopy directly visualises the colon and the terminal ileum. The endoscopist takes biopsies that the pathologist examines under microscope to confirm the inflammatory pattern and rule out alternative causes (infectious colitis, microscopic colitis, ischemic colitis).
• Imaging. For Crohn's in particular, MR enterography or CT enterography is often added to assess the small bowel, which is not fully accessible by colonoscopy.

How IBD is treated

IBD treatment is gastroenterology-led and follows a stepped approach matched to disease severity, location, and behaviour. The categories include:

• Aminosalicylates (5-ASA agents). First-line for mild to moderate ulcerative colitis. Less role in Crohn's.
• Corticosteroids. For inducing remission in flares. Not for long-term maintenance.
• Immunomodulators. Thiopurines (azathioprine, 6-mercaptopurine), methotrexate. Used for maintenance and for steroid-sparing.
• Biologics. Anti-TNF agents (infliximab, adalimumab), anti-integrin agents (vedolizumab), anti-IL-23/12 agents (ustekinumab, risankizumab), and others. These have transformed IBD outcomes in the last 20 years.
• Small molecule agents. JAK inhibitors and S1P modulators are newer additions for moderate-to-severe disease.
• Surgery. Sometimes necessary, particularly in Crohn's with strictures or fistulas, or in ulcerative colitis with disease refractory to medical management.

Where GDH fits in IBD is narrow and specific. It does not treat the inflammation, full stop. It cannot substitute for biologics or any other disease-modifying therapy. Its only legitimate role in IBD is as supportive care for IBS-pattern overlay symptoms (pain, bloating, urgency, altered bowel habit) that persist in patients whose IBD is otherwise in objective remission, with normal calprotectin and a clean scope. This pattern is sometimes called post-inflammatory IBS-like syndrome and shares enough mechanism with primary IBS that gut-brain therapies can offer real symptomatic relief without touching the underlying disease control. Any such work is done in coordination with the treating gastroenterologist.

Extra-intestinal manifestations

One feature that distinguishes IBD from IBS and SIBO is the range of extra-intestinal manifestations that can come along for the ride. Joint inflammation (peripheral arthritis, sacroiliitis, ankylosing spondylitis), skin findings (erythema nodosum, pyoderma gangrenosum), eye involvement (uveitis, episcleritis), liver and bile duct disease (primary sclerosing cholangitis), and bone density loss are all more common in IBD than in the general population. They reflect the systemic immune dysregulation that underlies the bowel disease. None of these features show up in IBS or SIBO. Their presence is another reason to be in IBD-specialist care rather than treating gut symptoms in isolation.

What changes in IBD when you achieve remission

Modern IBD care defines remission across several layers, and these layers do not always agree. Symptomatic remission means symptoms have settled. Biochemical remission means inflammatory markers (calprotectin, CRP) have normalised. Endoscopic remission means the bowel looks healed on scope. Histological remission means the biopsies look normal under the microscope. Deep remission usually refers to multiple of these layers being achieved at once. The treatment goal in modern IBD care has shifted from purely symptomatic control toward objective remission, because patients who achieve mucosal healing have lower long-term complication rates. The relevance for this guide: a patient who is in true objective remission but still has symptoms is a different clinical picture from a patient who is symptomatic and still has active inflammation. The first is where gut-brain therapies become reasonable. The second is where escalation of medical therapy is the right move.

The hard part of differential diagnosis is that the headline symptoms (abdominal pain, bloating, altered bowel habit) overlap heavily across the three conditions. The discriminators are in the specifics: the timing, the company the symptoms keep, and what shows up on objective testing.

Red flags for IBD

These are the features that should not be attributed to IBS without further workup:

• Visible blood in the stool. Bright red, dark, or mixed-in. IBS does not cause this. Ulcerative colitis classically does. Crohn's can. Hemorrhoids, fissures, and other anorectal sources also can, so the history matters.
• Unintentional weight loss. Pounds dropping off without trying suggests malabsorption or systemic inflammation, neither of which IBS produces.
• Nocturnal symptoms. Diarrhea that wakes you from sleep is not typical of IBS. IBS symptoms are usually quiet at night.
• Fevers. Especially in combination with abdominal pain, these point toward infection or active inflammation, not IBS.
• Iron-deficiency anemia. A signal of chronic blood loss or malabsorption.
• Family history of IBD or colorectal cancer in a first-degree relative. Lowers the threshold for endoscopy.
• New-onset symptoms after age 50. Onset of significant new bowel symptoms in this age range deserves a closer look.
• Severe ongoing pain unrelieved by passing stool. IBS pain is classically associated with defecation; pain that does not change with bowel habit warrants investigation.

Any of these features should be discussed with a physician. Identifying conditions that mimic IBS is exactly why a careful workup matters before settling on an IBS label.

Indicators that point toward SIBO

• Bloating that gets worse after carbohydrate-rich meals. Especially within 60 to 90 minutes. The hallmark of small-intestinal fermentation.
• Visible abdominal distension after eating. Not just a feeling. Patients often describe looking pregnant by evening.
• Excessive belching and gas. More pronounced than typical IBS bloating.
• Symptoms that flare on probiotics or fermented foods. Counterintuitive, but adding more bacteria to an already-overgrown small intestine often makes things worse.
• A history of risk factors. Prior bowel surgery, adhesions, scleroderma, long-term proton pump inhibitor use, diabetes with autonomic neuropathy, repeated antibiotic courses.
• Constipation that responds to motility support. Particularly the IMO subtype.

The IBS picture (when red flags are absent)

• Pain related to defecation. Pain that improves after passing stool is a classic Rome IV criterion.
• Pain associated with a change in stool form or frequency. The other Rome IV criterion.
• Symptoms that wax and wane with stress. Not unique to IBS, but very characteristic.
• Normal investigations. Normal CRP, normal calprotectin, normal scope (if done).
• Long-standing pattern. Most IBS does not arrive overnight. A pattern stretching back years is consistent.

The role of fecal calprotectin

Calprotectin deserves its own paragraph because it has quietly become one of the most useful single tests in primary-care gastroenterology. It is a protein released by neutrophils in the bowel wall when there is local inflammation. A simple stool sample measures it.

A low calprotectin in a patient with IBS-pattern symptoms makes IBD very unlikely and supports a confident IBS diagnosis without proceeding to colonoscopy. An elevated calprotectin does not by itself diagnose IBD (it can also rise in infections, NSAID-related enteropathy, and other conditions), but it is a clear signal that further investigation is warranted. For patients trying to avoid an invasive workup unless it is necessary, calprotectin is often the deciding test.

Why colonoscopy is sometimes still needed in IBS-pattern symptoms

Even with a clean clinical picture and a normal calprotectin, colonoscopy is sometimes done in IBS-pattern symptoms. Reasons include:

• Patient age crossing screening thresholds for colorectal cancer.
• Family history of colorectal cancer or polyps in a first-degree relative.
• New-onset symptoms in someone older than 50.
• Persistent diarrhea where microscopic colitis (which can have a normal calprotectin) is on the differential.
• Symptom evolution that does not match the original IBS pattern.
• Failure to respond to first-line management, prompting reassessment of the diagnosis.

The decision is individualised. Not every IBS patient needs a scope, and not every scope is for IBD specifically. Often it is to rule out the smaller-but-real list of conditions that look like IBS but are not.

Other conditions that mimic the IBS picture

Beyond IBD and SIBO, several other conditions can produce IBS-like symptoms and deserve a quick mention because they sometimes get missed when everyone settles too early on an IBS label. The list of common mimics includes:

• Celiac disease. A serological screen (tissue transglutaminase IgA with total IgA) is part of any thoughtful IBS workup, particularly in IBS-D pictures. Celiac is missed surprisingly often, and untreated it has serious long-term consequences.
• Microscopic colitis. Watery diarrhea, often in older women, with a normal-looking colon on scope. Diagnosis requires biopsies, which is why scoping a refractory diarrhea picture sometimes still finds something even when calprotectin is normal.
• Bile acid malabsorption. A frequently overlooked cause of IBS-D pattern. Treatment is straightforward (a bile acid sequestrant), but it requires getting the diagnosis right.
• Lactose or fructose malabsorption. Both can produce bloating, gas, and altered bowel habit. Both are tested with breath testing similar to SIBO testing but using different substrates.
• Pancreatic exocrine insufficiency. Greasy, hard-to-flush stools, weight loss, and bloating. Stool elastase is the standard screening test.
• Endometriosis. Cyclical bowel symptoms in women that track with the menstrual cycle should raise this possibility, particularly if pain dominates the picture.
• Pelvic floor dysfunction. A common cause of constipation and incomplete evacuation that can be misclassified as IBS-C and that responds to a different treatment (pelvic floor physiotherapy) than IBS proper.

None of these mimics are exotic, and a thorough workup typically considers the relevant ones based on the dominant symptom pattern. The overarching point is that "IBS" should be a positive Rome IV diagnosis after appropriate alternatives have been considered, not a default label applied when no one knows what else to call the symptoms.

The cleanest way to think about these three conditions is as overlapping circles, not separate boxes. A meaningful percentage of patients carry more than one diagnosis at once, which is exactly why a careful diagnostic sequence matters before treatment selection.

IBS plus SIBO

The most common overlap. Published estimates put the proportion of diarrhea-predominant IBS patients with positive SIBO breath testing somewhere between 30 and 50 percent. The number varies depending on the breath test methodology, the criteria used, and the population studied. The clinical implication is consistent across studies: a substantial subset of IBS-D patients have a microbial layer that is contributing to their symptoms.

What is harder is the reverse direction. Treating SIBO with antimicrobials produces meaningful symptom improvement in many patients, but it does not always resolve the IBS picture entirely. The visceral hypersensitivity, anxiety, and gut-brain dysregulation that characterise IBS often persist after the bacterial load drops. This is why many integrative gastroenterology protocols sequence the work: rule out and address SIBO first if breath testing is positive, then layer in gut-brain therapies for any residual symptom burden.

IBD with IBS-like overlay

Patients with IBD who are in objective remission (no active inflammation on scope, normal calprotectin, no flare biomarkers) sometimes continue to experience the symptoms that brought them in originally: pain, urgency, bloating, altered bowel habit. This is not the IBD acting up. It is what the literature calls post-inflammatory IBS-like syndrome, and it likely reflects long-term changes in visceral sensitivity, motility, and gut-brain signalling that persist even after the inflammatory driver is controlled.

The distinction matters for treatment. Treating an IBS-like overlay as if it were active inflammation leads to escalating immunosuppression that does not address the actual symptom driver. Treating it as IBS, with diet and gut-brain therapies, often works. The first job, always, is to confirm with the gastroenterologist that the IBD is in remission. The second is to rule out concurrent SIBO, which IBD patients are at higher risk of (because of strictures, prior surgery, or motility changes). Only then is gut-brain work the right next move.

Why diagnostic order matters

The single most consequential decision in this whole picture is what gets ruled out first. The standard sequence in good gastroenterology practice runs roughly as follows:

1. Take a careful history. Identify red flags and risk factors.
2. Run baseline labs and stool calprotectin to screen for inflammatory disease.
3. If red flags or elevated markers are present, refer for endoscopy with biopsy.
4. If the picture is clean and Rome IV criteria for IBS are met, treat as IBS.
5. If treatment for IBS does not produce an adequate response, consider a SIBO breath test, particularly in IBS-D and bloating-predominant pictures.
6. Layer treatments based on what the workup actually identified, not on a guess.

Skipping steps in either direction creates problems. Skipping the IBD workup risks treating real inflammation as functional symptoms. Skipping the IBS conversation risks chasing breath-test positives in patients whose dominant driver is gut-brain dysregulation. The point of the sequence is to match the treatment to what is actually wrong.

Two real-world patient pictures

To make the overlap concrete, consider two simplified clinical sketches that reflect patterns we see often in practice.

Patient A. Thirty-four-year-old woman, ten years of bloating and IBS-D after a bad gastroenteritis episode in her early twenties. No red flags. Calprotectin normal. Rome IV criteria met. Has tried low-FODMAP with partial response, has tried antispasmodics with marginal benefit, still wakes most days uncertain whether she will be able to leave the house in the morning. SIBO breath test was positive on lactulose with an early hydrogen rise. After a course of rifaximin, the bloating drops by 60 percent but the abdominal pain, urgency, and underlying gut-brain reactivity persist. The next clinical step that makes sense for her is the gut-brain layer: a structured GDH course, often combined with continued attention to diet and motility support. The SIBO antimicrobial work was necessary but not sufficient. The IBS picture remains and is now the dominant target.

Patient B. Twenty-eight-year-old man, sudden onset of bloody diarrhea and weight loss over six weeks. Calprotectin markedly elevated. Colonoscopy shows continuous inflammation from the rectum extending up the descending colon, biopsies confirm ulcerative colitis. Started on a 5-ASA agent, then escalated to a biologic when initial response was incomplete. Twelve months later, in objective remission with a normal calprotectin and a clean follow-up scope. He still has bloating, abdominal cramping, and intermittent urgency. This is not active IBD. It is post-inflammatory IBS-like overlay. His gastroenterologist confirms the disease control is good and that the residual symptoms are functional in nature. This is exactly the narrow scenario where adjunctive GDH can help, working alongside ongoing IBD maintenance therapy and not in place of it.

The same logic applies in reverse for SIBO. A patient with elevated calprotectin and a positive breath test is not someone in whom SIBO treatment alone is the answer; the inflammation needs a workup first. A patient with normal markers, no red flags, a positive Rome IV picture, and a positive breath test is someone for whom the order of operations is debatable but the eventual likely shape is sequenced multimodal care.

Gut-directed hypnotherapy (GDH) is a structured, manualised, evidence-based gut-brain therapy. It is most rigorously studied in IBS, where it is recognised in major guidelines as a first-line treatment option. Its mechanism is to use the absorbed, focused state characteristic of clinical hypnosis to reduce visceral hypersensitivity, calm autonomic reactivity, and rebuild healthier gut-brain signalling patterns. The Manchester Protocol developed by Whorwell's clinic is the most widely studied version, typically delivered across 12 weekly sessions with daily home audio practice.

The honest position on where GDH fits across these three diagnoses looks like this:

For IBS: first-line evidence-based therapy

In IBS, GDH sits in the small group of treatments with strong direct evidence for response. The largest published outcome series, Miller 2015 (PMID 25736234), reported a 76 percent response rate to the Manchester Protocol in 1,000 consecutive refractory IBS patients, with response defined as a 50 percent or greater improvement on validated symptom scoring. This is real-world clinic data rather than a randomised trial, but it is the largest single benchmark in the literature. Major IBS treatment guidelines now list gut-directed hypnotherapy alongside dietary and pharmacological options as a recommended evidence-based intervention. For specifically how it works in IBS, see our deeper page on GDH for IBS.

For SIBO: adjunctive, not curative

SIBO is a microbial problem and GDH is not antimicrobial. It does not eradicate bacteria, it does not change breath gas profiles, and it does not substitute for the antibiotic, prokinetic, and dietary work that is the backbone of SIBO management. What it can do is address the residual gut-brain layer that often persists after a successful antimicrobial course. For patients with overlapping SIBO and IBS pictures, GDH is most often used after the antimicrobial phase to consolidate gains and reduce the visceral hypersensitivity that is left over.

For IBD: supportive only, for the IBS-pattern overlay

In IBD, GDH does not treat inflammation. It cannot. Active disease requires medical management led by a gastroenterologist, and nothing in a hypnotherapy session changes the immune-mediated inflammatory cascade. The narrow legitimate use case is for patients whose IBD is in confirmed objective remission (clean scope, normal calprotectin) but who continue to have IBS-pattern symptoms (pain, urgency, bloating, altered bowel habit). In that scenario, the symptoms behave more like IBS than like IBD, and the gut-brain mechanisms that GDH targets are relevant. Any such work happens in coordination with the treating gastroenterologist, not as a substitute for ongoing medical care.

Practical access and what sessions look like

The clinical commitment for the Manchester Protocol is typically 8 to 12 weekly sessions with daily home audio practice. Sessions can be delivered virtually across Canada or in person in Calgary, both at the same fee structure. Per-session cost is $220 CAD, with a standard initial commitment of 3 sessions ($660 CAD total) before any decision to continue. Continuation beyond the initial 3 sessions is optional. There are no admin fees. Sessions are paid at time of service, and a detailed receipt is provided that includes the practitioner's ARCH registration number.

The conditions worked with in this practice include IBS across all subtypes (IBS-D, IBS-C, IBS-M, IBS-U), SIBO as adjunct to medical treatment, functional dyspepsia, post-infectious IBS, visceral hypersensitivity, and IBS with anxiety overlap. Patients in IBD remission with persistent IBS-pattern symptoms are seen on a case-by-case basis with confirmation that the gastroenterologist supports the adjunctive role. Patients with active IBD, undiagnosed red flags, or untreated SIBO are referred back to medical care first.

What progress typically looks like

The Manchester Protocol research and broader GDH literature suggest that response, when it happens, typically becomes evident within the first three to four sessions. That is part of why the standard initial commitment of 3 sessions is structured the way it is: it gives both the practitioner and the patient enough data to know whether the protocol is moving the picture in the right direction. Patients who are responding usually report some combination of reduced visceral pain, calmer post-meal periods, less anticipatory anxiety around food and outings, and a sense that the bowel is "quieter in the background" even before symptoms have fully resolved. Patients who are not responding usually know it too. Honest assessment after the initial commitment is the right time to decide whether to continue, switch approaches, or layer in something else.

Where GDH does not produce response in the first three sessions, the most common reasons are: the dominant driver is not gut-brain (it is structural, microbial, or inflammatory and was not adequately addressed first); hypnotic responsiveness is on the lower end of the spectrum and a different gut-brain modality (CBT-for-IBS, mindfulness-based stress reduction) may suit better; or untreated comorbid anxiety, depression, or trauma is consuming the bandwidth that the GDH work needs. None of these are failures of the patient. They are signals about what the next move should be.

A note on insurance coverage

Hypnotherapy is generally not directly covered under Canadian extended health benefit plans. Some clients can claim related programs (stress management, behavioural change) under a Wellness Spending Account (WSA) if their plan offers one. Coverage rules depend entirely on plan design, so check with your insurance provider before booking.

The structural reason behind this is straightforward: hypnotherapy is not a regulated health profession in Alberta or in most other Canadian provinces. As a consequence, paramedical insurance categories (which follow provincial regulated profession lists) typically do not include it as a direct line item, provincial public health insurance plans do not cover it, and fees do not qualify as CRA-eligible medical expenses in those provinces. The exception is hypnosis performed by a regulated psychologist within a psychology practice, which is treated as a psychology session under standard psychology benefits.